Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
VOR
VOR
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
VOR News
Vor Biopharma Appoints Two New Board Members to Support $150M PIPE Financing
Dec 23 2025
Globenewswire
Vor Bio Secures $150 Million in Private Placement at $10.81 per Share
Dec 15 2025
Newsfilter
J.P. Morgan Initiates Coverage on Lead Asset with Overweight Rating, Boosting Bio Shares
Dec 09 2025
SeekingAlpha
Vor Biopharma (VOR) Receives Upgrade to Buy: Key Information You Need to Know
Nov 25 2025
NASDAQ.COM
HC Wainwright & Co. Upholds Buy Rating for Vor Biopharma (VOR)
Nov 15 2025
NASDAQ.COM
HC Wainwright & Co. Reaffirms Buy Rating for Vor Biopharma, Adjusts Price Target to $32
Nov 14 2025
Benzinga
Dow Rises Over 300 Points; Energy Vault Holdings Stock Soars
Nov 11 2025
Benzinga
Vor Biopharma Raises $100 Million Following Positive Kidney Disease Trial Results
Nov 11 2025
Benzinga
US Stocks Show Varied Performance; Sea Shares Rise Following Q3 Earnings Report
Nov 11 2025
Benzinga
Rocket Lab Shares Surge Over 9%; Check Out 20 Stocks Making Moves in Premarket Trading
Nov 11 2025
Benzinga
Vor Biopharma Announces Public Offering of 10 Million Shares at $10.00 Each
Nov 11 2025
NASDAQ.COM
Vor Biopharma Shares Drop 26% as Company Prices $100M Equity Offering at $10 per Share
Nov 11 2025
SeekingAlpha
Telitacicept Successfully Met Primary Goal of Lowering Proteinuria in Stage A of Phase 3 Clinical Trial for IgA Nephropathy in China
Nov 08 2025
Newsfilter
Vor Biopharma Names Jeremy Sokolove as Its New Chief Medical Officer
Nov 03 2025
NASDAQ.COM
Telitacicept Shows Long-lasting Effectiveness and Positive Safety Record in 48-Week Phase 3 Open-Label Extension Study for Generalized Myasthenia Gravis in China
Oct 29 2025
Newsfilter
Vor Bio to Present Late-Breaking Oral Update on Phase 3 IgA Nephropathy Clinical Trial in China at ASN Kidney Week 2025
Oct 17 2025
Newsfilter
Show More News
